SCHEMBL5815787

SCHEMBL5815787

CCCC(=O)Nc1ccc2[nH]c(-c3cn[nH]c3)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.49
ROCK2 O75116 1/20 0.46
TP53 P04637 1/20 0.45
FYN P06241 2/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
AURKA O14965 4/20 0.44
CCNA2 P20248 4/20 0.44
CDK2 P24941 4/20 0.44
TTK P33981 4/20 0.44
PDE10A Q9Y233 1/20 0.44
ITK Q08881 1/20 0.44
MAPT P10636 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
NAMPT P43490 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 2/20 0.43
AURKB Q96GD4 1/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480489 0.92 ITK (0.46) ROCK2TP53FYNCNR1CNR2
SCHEMBL6481076 0.91 PDE10A (0.51) KCNQ2ROCK2FYNAURKACCNA2
SCHEMBL5755746 0.84 NAMPT (0.51) KCNQ2ROCK2FYNAURKACCNA2
SCHEMBL5755889 0.83 PDE10A (0.50) KCNQ2ROCK2FYNAURKACCNA2
SCHEMBL5756127 0.82 TNIK (0.50) KCNQ2ROCK2FYNAURKACCNA2
SCHEMBL5814937 0.82 ROCK2 (0.52) ROCK2AURKAALDH1A1KDM4ENAMPT
SCHEMBL5754846 0.81 ROCK2 (0.47) KCNQ2ROCK2FYNAURKACCNA2
SCHEMBL5760150 0.79 ROCK2 (0.64) ROCK2FYNITKMAPTNAMPT
SCHEMBL5820546 0.79 PARP14 (0.47) ROCK2FYNAURKACCNA2CDK2
SCHEMBL5820065 0.78 NPC1 (0.59) ROCK2ITKMAPTALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648884-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2006-04-26 EP disclosed
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed
WO-2005005414-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 KCNQ2 1417/4885ROCK2 600/4885TP53 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.